More than 1,000 eye care professionals worldwide have been using the AdaptDx® and AdaptDx Pro™ to test for impaired dark adaptation, the earliest biomarker of age-related macular degeneration. Our customers tell the story of how they’re fighting against preventable blindness by identifying AMD at its earliest stages and closely monitoring its progression.
I think it’s excellent that my doctor has AdaptDx because it can detect AMD at a very early stage. There’s a history of AMD in my family so I was very motivated to take the test.
The primary goal of every optometrist is to preserve the vision of our patients. Detecting, monitoring, and treating AMD are imperative to our mission. We can detect earlier than ever before and manage AMD by doing all we can to prevent progression to advanced stages and complications such as CNV.
The customer service education training and support that I receive from MacuLogix is second to none of any of the other companies in our profession.
I think it’s very important to see an eye doctor that has the latest technology because it gives you access to knowledge and the ability to find or diagnose issues with your eyes.
The AdaptDx Pro with Theia is a huge opportunity to differentiate yourself, become more medical, and have a more successful practice as well.
When I look at the future of managing macular degeneration, I see the AdaptDx as the essential tool in AMD management just as now I see the OCT as the essential tool in managing glaucoma in its earliest stages. By finding a disease early, and intervening appropriately we have the best chance of altering the course.
I have advanced AMD and I wish the AdaptDx Pro™ had been available for me years ago. Maybe I wouldn’t be here today. I wouldn’t want anyone to go through this if there’s a way to prevent it or treat it early and give people a better quality of life for longer period of time. I encourage everybody. Take advantage of this technology. It’s wonderful.
The AdaptDx Pro gives us the opportunity to change the future of macular degeneration care because it allows us to screen everyone at risk and identify macular degeneration earlier. The whole objective is to reduce the number of patients losing vision from macular degeneration.
The AdaptDx was painless and easy to follow. I had to push a clicker when I would see a certain light. They told me it was a little lengthy but it didn’t seem that long.
Macular degeneration is 3 times more prevalent than glaucoma and diabetic retinopathy combined. So why would I not use the AdaptDx test on everybody over the age of 50? Oh, and did I mention it helps you identify signs of subclinical AMD before you can see drusen or mottling in the eye itself?